Universal Health Shares Drop 21% YTD: Should You Buy Now?

Image Source: Zacks Investment Research

ACA/exchange exposure became a major concern early in the year. Those concerns are now showing up operationally. UHS said second-quarter exchange volumes fell about 15% YoY, shifting some patients toward self-pay. Also, volumes have been weaker than UHS originally expected.

First-quarter acute-care volumes were hurt by a weak flu and respiratory season and winter weather. By second quarter, management concluded that some softness was structural rather than just weather. It lowered 2026 same-facility growth assumptions to 1.5-2.5% for acute admissions, from 2-3%, and 1-2% for behavioral patient days, also from 2-3%. It lowered 2026 adjusted EBITDA guidance from $2.641-$2.789 billion to $2.610-$2.717 billion, cutting the midpoint by about $50 million.

As a result, analyst estimates have reset sharply. However, the estimates still indicate significant growth going forward.

Estimates for UHS

The Zacks Consensus Estimate for 2026 adjusted earnings stands at $23.08 per share, indicating year-over-year growth of 6.2%, followed by a projected 6.4% increase in 2027. Both witnessed one upward estimate revision over the past week, against one downward movement. Revenue estimates imply growth of 7.1% in 2026 and 5.3% in 2027.

UHS has exceeded earnings expectations in three of the past four quarters and missed once, delivering an average surprise of 8.3%.

UHS’ Valuation

The share price fall created a valuation cushion. The stock trades at a forward earnings multiple of 7.16X, below its five-year median of 10.77X and the industry average of 11.24X. Relative to peers, the valuation gap is even clearer. Tenet Healthcareand HCA Healthcaretrade at forward 12-month P/E ratios of 13.47X and 13.05X, respectively.

For a profitable hospital operator still growing earnings, that multiple implies the market is pricing in substantial reimbursement and operating problems. Even a modest normalization of the valuation multiple could produce meaningful upside. UHS now has a Value Score of A.

UHS shares trade below the average price target of $192.81, suggesting a potential upside of roughly 11.9%. While target estimates range widely from $290 to $166, reflecting varying risk assumptions, the overall outlook remains constructive.

Positives to Notice

The underlying business is still growing despite the bad headlines. First-half 2026 revenue increased 8.9%, and adjusted EPS rose from $10.19 to $11.60. Earnings estimates for both 2026 and 2027 also point to continued growth, although the expected growth is lower than previously anticipated.

UHS itself has been aggressively buying shares. The company repurchased $447.5 million of stock in the first half of 2026, including $320.3 million in the second quarter at an average price of about $169. It still had $977.6 million of repurchase authorization remaining at June 30.

UHS closed the $835 million Talkspace acquisition on Aug. 17. Strategically, the deal expands UHS beyond its traditional inpatient behavioral-health footprint into virtual therapy and psychiatry, giving it access to thousands of providers and a very large insured population. The potential to connect virtual care, outpatient treatment, inpatient facilities and post-discharge care within the same behavioral-health ecosystem can create massive opportunity for the company.

Conclusion

UHS’ steep share-price decline has created a compelling valuation opportunity, supported by continued earnings growth, aggressive share repurchases and the strategic addition of Talkspace. However, weaker volumes, ACA exchange pressures, reimbursement uncertainty and reduced growth expectations continue to cloud the near-term outlook.

With meaningful upside potential balanced by execution and policy risks, the risk-reward appears fairly balanced at current levels. Therefore, investors may prefer to wait for clearer operating improvement before investing. UHS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research